临床研究中的胰岛素类药物进展

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (0 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Insulin is mainly used in the clinical treatment of dependent diabetes mellitus as well as some non-insulin-dependent diabetes. In recent years, with the increase of diabetic patients and improvement of therapeutic regimen, the use of insulin for diabetes treatment becomes more widely. Currently, developing insulin drugs mainly include insulin analogues and their new formulations. By searching the relevant literature, investigational insulin drugs in different clinical stages in recent three years in abroad were introduced systematically. It was pointed out that developing insulin injection formulations mainly include long-acting insulin, while non-injection formulations include almost all non-injectable routes of administration, such as oral medication, pulmonary drug delivery, transdermal delivery etc.. Among which, the development of non-injection formulations was the continuous chasing target of many pharmaceutical enterprises.

Key words： insulin analogue new formulation clinical research HbA1c side effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Jun-de
	LIU Shao-hua
	TANG Mi

Cite this article:

LI Jun-de,LIU Shao-hua,TANG Mi. Progress of Insulin Drugs in Clinical Research[J]. CCI, 2014, 37(12): 27-30.

URL:

http://www.mtyhg.com.cn/EN/ OR http://www.mtyhg.com.cn/EN/Y2014/V37/I12/27

[ 1 ]     张庆兰. 胰岛素制剂的分类及研究进展[ J ]. 临床合理用药, 2013, 6(6B): 148-150.

[ 2 ]     Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal [ J ] . J Diabetes Sci Technol, 2009, 3(3): 568-584.

[ 3 ]     Mandal T K. Inhaled insulin for diabetes mellitus [ J ]. Am J Health Syst Pharm, 2005, 62(13): 1359-1364.

[ 4 ]     Owens D R, Zinman B, Bolli G. Alternative routes of insulin deliv-ery [ J ]. Diabete Med, 2003, 2(11): 886-898.

[ 5 ]     Moore M C, Smith M S, Sinha V P, etc. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism [ J ]. Diabetes，2014, 63(2): 494-504.

[ 6 ]     Rotenstein L S, Ran N, Shivers J P. Opportunities and challenges for biosimilars: What's on the horizon in the global insulin market[ J ]. Clin Diabetes, 2012, 30(4): 138-150.

[ 7 ]     Cox J. Sanofi Announces new phase 3 results for investigational new insulin U300 [EB/OL]. [2014-01-14].http://m-en.sanofi.com/Im-ages/35096_20131203_U300_ED_Ⅱ__ⅢIV_ JPI_en.pdf.

[ 8 ]     Maiorino M I, Petrizzo M, Capuano A, etc. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes [ J ]. Expert Opin Biol Ther, 2014, 14(6): 799 - 808.

[ 9 ]     Palermo A, Napoli N, Manfrini S, et al. Buccal spray insulin in sub-jects with impaired glucose tolerance: the prevoral study [ J ]..

Diabetes Obes Metab，2011, 13(1): 42-46.

[10]     Eldor R, Arbit E, Corcos A, et al. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study [J]. PLoS One, 2013, 8(4):e59524.

[11]     Geho W B, Geho H C, Lau J R., et al. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evalua-tion [ J ]. J Diabetes Sci Technol., 2009, 3(6): 1451-1459.

[12]     Geho W B, Rosenberg L N, Schwartz S L, et al. A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus [ J ]. J Diabetes Sci Technol, 2014, 8(3): 551-559.

[13]     杜海洲. 国际抗糖尿病药物研发新进展[ J ]. 药学进展, 2014, 38(3): 185-195.